Profiles

Keywords
Last Name
Institution

Cynthia Comella

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences, Section of Parkinson's Disease and Movement Disorders
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7004269522


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Christiansen C, Moore C, Schenkman M, Kluger B, Kohrt W, Delitto A, Berman B, Hall D, Josbeno D, Poon C, Robichaud J, Wellington T, Jain S, Comella C, Corcos D, Melanson E. Factors Associated With Ambulatory Activity in De Novo Parkinson Disease. J Neurol Phys Ther. 2017 Apr; 41(2):93-100. PMID: 28263256.
      View in: PubMed
    2. Rafferty MR, Prodoehl J, Robichaud JA, David FJ, Poon C, Goelz LC, Vaillancourt DE, Kohrt WM, Comella CL, Corcos DM. Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial. J Neurol Phys Ther. 2017 Jan; 41(1):21-30. PMID: 27977518.
      View in: PubMed
    3. LaHue SC, Comella CL, Tanner CM. The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Mov Disord. 2016 Oct; 31(10):1444-1454. PMID: 27477046.
      View in: PubMed
    4. Comella CL, Camba GC, Truong D, Espay AJ, Snyder D, Marchese D, Trosch R. Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study. PM R. 2016 Sep; 8(9S):S256-S257. PMID: 27673052.
      View in: PubMed
    5. David FJ, Robichaud JA, Vaillancourt DE, Poon C, Kohrt WM, Comella CL, Corcos DM. Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial. J Neurophysiol. 2016 Nov 01; 116(5):2298-2311. PMID: 27582297.
      View in: PubMed
    6. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10; 86(19):1818-26. PMID: 27164716; PMCID: PMC4862245 [Available on 05/10/17].
    7. LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, Jinnah HA, Rosen AR, Hedera P, Comella CL, Weissbach A, Junker J, Jankovic J, Barbano RL, Reich SG, Rodriguez RL, Berman BD, Chouinard S, Severt L, Agarwal P, Stover NP. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet. 2016 Jun; 2(3):e69. PMID: 27123488; PMCID: PMC4830199.
    8. Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9. PMID: 26971359; PMCID: PMC4833533 [Available on 04/01/17].
    9. Bledsoe IO, Comella CL. Botulinum Toxin Treatment of Cervical Dystonia. Semin Neurol. 2016 Feb; 36(1):47-53. PMID: 26866496.
      View in: PubMed
    10. Fraint A, Vittal P, Comella C. Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? Ther Clin Risk Manag. 2016; 12:147-54. PMID: 26917963; PMCID: PMC4751901.
    11. Pal GD, Hall D, Ouyang B, Phelps J, Alcalay R, Pauciulo MW, Nichols WC, Clark L, Mejia-Santana H, Blasucci L, Goetz CG, Comella C, Colcher A, Gan-Or Z, Rouleau GA, Marder K. Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. Mov Disord Clin Pract. 2016 Sep-Oct; 3(5):465-471. PMID: 27709117.
      View in: PubMed
    12. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10. PMID: 26569098.
      View in: PubMed
    13. Högl B, Comella C. Therapeutic advances in restless legs syndrome (RLS). Mov Disord. 2015 Sep 15; 30(11):1574-9. PMID: 26371624.
      View in: PubMed
    14. David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, Comella CL, Vaillancourt DE, Corcos DM. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63. PMID: 26148003; PMCID: PMC4609235 [Available on 10/01/16].
    15. Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT. Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology. Mov Disord Clin Pract. 2015 Jun; 2(2):135-141. PMID: 27088112.
      View in: PubMed
    16. Jost WH, Benecke R, Hauschke D, Jankovic J, Kanovský P, Roggenkämper P, Simpson DM, Comella CL. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26. PMID: 25897202; PMCID: PMC4389813.
    17. Tanner CM, Comella CL. When brawn benefits brain: physical activity and Parkinson's disease risk. Brain. 2015 Feb; 138(Pt 2):238-9. PMID: 25627233; PMCID: PMC4394643.
    18. Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol. 2015; 262(4):837-48. PMID: 25605434; PMCID: PMC4544552.
    19. Yan L, Hicks M, Winslow K, Comella C, Ludlow C, Jinnah HA, Rosen AR, Wright L, Galpern WR, Perlmutter JS. Secured web-based video repository for multicenter studies. Parkinsonism Relat Disord. 2015 Apr; 21(4):366-71. PMID: 25630890; PMCID: PMC4372455.
    20. Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM. Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review. J Parkinsons Dis. 2015; 5(4):993. PMID: 26683786.
      View in: PubMed
    21. Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM. Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review. J Parkinsons Dis. 2015; 5(3):621. PMID: 26406143.
      View in: PubMed
    22. Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM. Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review. J Parkinsons Dis. 2015; 5(1):21-41. PMID: 25374272.
      View in: PubMed
    23. Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack Adams A, Brin MF. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93. PMID: 25595221.
      View in: PubMed
    24. Planetta PJ, Kurani AS, Shukla P, Prodoehl J, Corcos DM, Comella CL, McFarland NR, Okun MS, Vaillancourt DE. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp. 2015 Mar; 36(3):1165-79. PMID: 25413603; PMCID: PMC4950674.
    25. Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord. 2015 Feb; 30(2):278-83. PMID: 25393808; PMCID: PMC4318772.
    26. Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20. PMID: 25186131.
      View in: PubMed
    27. Kurani AS, Seidler RD, Burciu RG, Comella CL, Corcos DM, Okun MS, MacKinnon CD, Vaillancourt DE. Subthalamic nucleus--sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease. Neurobiol Aging. 2015 Jan; 36(1):462-9. PMID: 25095723; PMCID: PMC4268125.
    28. Prodoehl J, Rafferty MR, David FJ, Poon C, Vaillancourt DE, Comella CL, Leurgans SE, Kohrt WM, Corcos DM, Robichaud JA. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22. PMID: 24961994; PMCID: PMC4276552.
    29. Narayanaswami P, Showers D, Levi B, Showers M, Jones EC, Busis NA, Comella CL, Pulst SM, Hosey JP, Griggs RC. State neurologic societies and the AAN: Strengthening neurology for the future. Neurol Clin Pract. 2014 Jun; 4(3):247-255. PMID: 25110622.
      View in: PubMed
    30. Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, Schwartz M, Brin MF. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19. PMID: 24752807; PMCID: PMC4098041.
    31. Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014 Apr; 20(4):405-8. PMID: 24486141.
      View in: PubMed
    32. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2014 Jan; 71(1):62-7. PMID: 24190026; PMCID: PMC3947132.
    33. Comella CL. Treatment of restless legs syndrome. Neurotherapeutics. 2014 Jan; 11(1):177-87. PMID: 24363103; PMCID: PMC3899490.
    34. Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA. Designing clinical trials for dystonia. Neurotherapeutics. 2014 Jan; 11(1):117-27. PMID: 24282121; PMCID: PMC3899487.
    35. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83. PMID: 23868503.
      View in: PubMed
    36. Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707. PMID: 23779062; PMCID: PMC3834167.
    37. Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A. Dystonia rating scales: critique and recommendations. Mov Disord. 2013 Jun 15; 28(7):874-83. PMID: 23893443; PMCID: PMC4207366.
    38. Jinnah HA, Berardelli A, Comella C, Defazio G, Delong MR, Factor S, Galpern WR, Hallett M, Ludlow CL, Perlmutter JS, Rosen AR. The focal dystonias: current views and challenges for future research. Mov Disord. 2013 Jun 15; 28(7):926-43. PMID: 23893450; PMCID: PMC3733486.
    39. Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013 Aug; 12(8):747-55. PMID: 23726851; PMCID: PMC3714436.
    40. Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22. PMID: 23674400; PMCID: PMC3748146.
    41. Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, Jankovic J. Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2013; 3. PMID: 23610743; PMCID: PMC3629862.
    42. Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug; 28(9):1230-40. PMID: 23536417; PMCID: PMC3701730.
    43. Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403. PMID: 23505500; PMCID: PMC3594313.
    44. Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease. JAMA Neurol. 2013 Jan; 70(1):100-6. PMID: 23318516; PMCID: PMC3645004.
    45. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9. PMID: 23032792; PMCID: PMC4157921.
    46. Corcos DM, Comella CL, Goetz CG. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 May 03; 366(18):1737-8; author reply 1738. PMID: 22551137.
      View in: PubMed
    47. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 01; 78(18):1434-40. PMID: 22442429; PMCID: PMC3345785.
    48. Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011 Dec; 17(10):740-4. PMID: 21856206; PMCID: PMC3221786.
    49. Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140. PMID: 22054223; PMCID: PMC3220636.
    50. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9. PMID: 21764407.
      View in: PubMed
    51. Thobois S, Taira T, Comella C, Moro E, Bressman S, Albanese A. Pre-operative evaluations for DBS in dystonia. Mov Disord. 2011 Jun; 26 Suppl 1:S17-22. PMID: 21692107.
      View in: PubMed
    52. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8. PMID: 21520284.
      View in: PubMed
    53. Charous SJ, Comella C. Dystonias of the head and neck: An overview. Ear Nose Throat J. 2011 Feb; 90(2):E4. PMID: 21328221.
      View in: PubMed
    54. Charous SJ, Comella CL, Fan W. Jaw-opening dystonia: Quality of life after botulinum toxin injections. Ear Nose Throat J. 2011 Feb; 90(2):E9. PMID: 21328222.
      View in: PubMed
    55. Robottom BJ, Weiner WJ, Comella CL. Early-onset primary dystonia. Handb Clin Neurol. 2011; 100:465-79. PMID: 21496603.
      View in: PubMed
    56. Videnovic A, Comella CL. Sleep disorders in Parkinson's disease. Handb Clin Neurol. 2011; 99:997-1010. PMID: 21056240.
      View in: PubMed
    57. Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology. 2011 Jan 25; 76(4):319-26. PMID: 21205674; PMCID: PMC3034420.
    58. Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16. PMID: 20931631.
      View in: PubMed
    59. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100. PMID: 21092386; PMCID: PMC3366462.
    60. Prodoehl J, Spraker M, Corcos D, Comella C, Vaillancourt D. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. Mov Disord. 2010 Oct 15; 25(13):2035-43. PMID: 20725915; PMCID: PMC2952037.
    61. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22. PMID: 20837857; PMCID: PMC3329730.
    62. Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010 Aug 15; 25(11):1708-14. PMID: 20589875; PMCID: PMC2928867.
    63. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010 Aug 15; 25(11):1627-32. PMID: 20544810.
      View in: PubMed
    64. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8. PMID: 20558392; PMCID: PMC3329757.
    65. Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease. Hum Brain Mapp. 2010 Dec; 31(12):1928-41. PMID: 20225221.
      View in: PubMed
    66. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Aug; 32(7):775-9. PMID: 20182943; PMCID: PMC2911493.
    67. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22. PMID: 20008657; PMCID: PMC2837584.
    68. Zauber SE, Watson N, Comella CL, Bakay RA, Metman LV. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. J Neurosurg. 2009 Feb; 110(2):229-33. PMID: 18976055.
      View in: PubMed
    69. Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 1. Eur Neurol. 2009; 61(4):193-205. PMID: 19176960.
      View in: PubMed
    70. Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early Parkinson's disease. Part 2. Eur Neurol. 2009; 61(4):206-15. PMID: 19176961.
      View in: PubMed
    71. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009 Apr 21; 72(16):1378-84. PMID: 19129507; PMCID: PMC2677508.
    72. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009 Oct; 54(5):628-33. PMID: 19103214; PMCID: PMC4782588.
    73. Robichaud JA, Pfann KD, Leurgans S, Vaillancourt DE, Comella CL, Corcos DM. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease? Clin Neurophysiol. 2009 Feb; 120(2):390-7. PMID: 19084473; PMCID: PMC2679966.
    74. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5. PMID: 18695158; PMCID: PMC2937041.
    75. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60. PMID: 18546321.
      View in: PubMed
    76. Prodoehl J, Corcos DM, Leurgans S, Comella CL, Weis-McNulty A, MacKinnon CD. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia. J Mot Behav. 2008 Jul; 40(4):301-13. PMID: 18628107; PMCID: PMC2657478.
    77. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706. PMID: 18458230.
      View in: PubMed
    78. Comella CL. Sleep disorders in Parkinson's disease. Curr Treat Options Neurol. 2008 May; 10(3):215-21. PMID: 18579025.
      View in: PubMed
    79. Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14(5):407-14. PMID: 18325821.
      View in: PubMed
    80. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 2: Treatment of motor symptoms. Am J Manag Care. 2008 Mar; 14(2 Suppl):S49-58. PMID: 18402508.
      View in: PubMed
    81. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008 Mar; 14(2 Suppl):S40-8. PMID: 18402507.
      View in: PubMed
    82. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008 Mar; 14(2 Suppl):S59-69. PMID: 18402509.
      View in: PubMed
    83. Comella CL. The treatment of cervical dystonia with botulinum toxins. J Neural Transm (Vienna). 2008; 115(4):579-83. PMID: 17994181.
      View in: PubMed
    84. Comella CL. Sleep disorders in Parkinson's disease: an overview. Mov Disord. 2007 Sep; 22 Suppl 17:S367-73. PMID: 18175398.
      View in: PubMed
    85. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, Marsh L, Nail L, Shulman L, Taylor CB. Fatigue in Parkinson's disease: a review. Mov Disord. 2007 Feb 15; 22(3):297-308. PMID: 17133511.
      View in: PubMed
    86. Iranzo A, Comella CL, Santamaria J, Oertel W. Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord. 2007; 22 Suppl 18:S424-30. PMID: 17534950.
      View in: PubMed
    87. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5. PMID: 17190952.
      View in: PubMed
    88. Park M, Comella CL, Leurgans SE, Fan W, Wilson RS, Bennett DA. Association of daytime napping and Parkinsonian signs in Alzheimer's disease. Sleep Med. 2006 Dec; 7(8):614-8. PMID: 17023213.
      View in: PubMed
    89. Prodoehl J, MacKinnon CD, Comella CL, Corcos DM. Rate of force production and relaxation is impaired in patients with focal hand dystonia. Parkinsonism Relat Disord. 2006 Sep; 12(6):363-71. PMID: 16731028; PMCID: PMC2094389.
    90. Comella CL, Thompson PD. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol. 2006 Feb; 13 Suppl 1:16-20. PMID: 16417593.
      View in: PubMed
    91. Prodoehl J, MacKinnon CD, Comella CL, Corcos DM. Strength deficits in primary focal hand dystonia. Mov Disord. 2006 Jan; 21(1):18-27. PMID: 16127719.
      View in: PubMed
    92. Comella CL. Can families be screened for cervical dystonia using a telephone interview? Nat Clin Pract Neurol. 2006 Jan; 2(1):20-1. PMID: 16932515.
      View in: PubMed
    93. Comella CL. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl. 2006; (70):349-55. PMID: 17017552.
      View in: PubMed
    94. Hinson VK, Cubo E, Comella CL, Goetz CG, Leurgans S. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7. PMID: 16108025.
      View in: PubMed
    95. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 08; 65(9):1423-9. PMID: 16275831.
      View in: PubMed
    96. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91. PMID: 15736159.
      View in: PubMed
    97. Itin I, Comella CL. Restless legs syndrome. Prim Care. 2005 Jun; 32(2):435-48. PMID: 15935194.
      View in: PubMed
    98. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005 Apr 26; 64(8):1450-1. PMID: 15851743.
      View in: PubMed
    99. Robichaud JA, Pfann KD, Vaillancourt DE, Comella CL, Corcos DM. Force control and disease severity in Parkinson's disease. Mov Disord. 2005 Apr; 20(4):441-50. PMID: 15593316.
      View in: PubMed
    100. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord. 2005; 20 Suppl 11:S30-7. PMID: 15822107.
      View in: PubMed
    101. Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve. 2004 May; 29(5):628-44. PMID: 15116366.
      View in: PubMed
    102. Pfann KD, Robichaud JA, Gottlieb GL, Comella CL, Brandabur M, Corcos DM. Muscle activation patterns in point-to-point and reversal movements in healthy, older subjects and in subjects with Parkinson's disease. Exp Brain Res. 2004 Jul; 157(1):67-78. PMID: 14991213.
      View in: PubMed
    103. Robichaud JA, Pfann KD, Comella CL, Brandabur M, Corcos DM. Greater impairment of extension movements as compared to flexion movements in Parkinson's disease. Exp Brain Res. 2004 May; 156(2):240-54. PMID: 14747885.
      View in: PubMed
    104. Comella C. Sleep episodes in Parkinson's disease: more questions remain. Sleep Med. 2003 Jul; 4(4):267-8. PMID: 14592295.
      View in: PubMed
    105. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61. PMID: 12796526.
      View in: PubMed
    106. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003 Mar; 18(3):303-12. PMID: 12621634.
      View in: PubMed
    107. Comella CL. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep. 2003 Mar; 3(2):173-80. PMID: 12583848.
      View in: PubMed
    108. Goldman JG, Comella CL. Treatment of dystonia. Clin Neuropharmacol. 2003 Mar-Apr; 26(2):102-8. PMID: 12671530.
      View in: PubMed
    109. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003 Jan 14; 60(1):69-73. PMID: 12525720.
      View in: PubMed
    110. Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81. PMID: 12735785.
      View in: PubMed
    111. Robichaud JA, Pfann KD, Comella CL, Corcos DM. Effect of medication on EMG patterns in individuals with Parkinson's disease. Mov Disord. 2002 Sep; 17(5):950-60. PMID: 12360544.
      View in: PubMed
    112. Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology. 2002 Feb 26; 58(4 Suppl 1):S87-92. PMID: 11909990.
      View in: PubMed
    113. Comella CL. Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA. 2002 Jan 23-30; 287(4):509-11. PMID: 11798375.
      View in: PubMed
    114. Pfann KD, Buchman AS, Comella CL, Corcos DM. Control of movement distance in Parkinson's disease. Mov Disord. 2001 Nov; 16(6):1048-65. PMID: 11748736.
      View in: PubMed
    115. Kompoliti K, Goetz CG, Leurgans S, Raman R, Comella CL. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519. PMID: 11673608.
      View in: PubMed
    116. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8. PMID: 11402109.
      View in: PubMed
    117. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62. PMID: 11222787.
      View in: PubMed
    118. Louis ED, Barnes L, Wendt KJ, Ford B, Sangiorgio M, Tabbal S, Lewis L, Kaufmann P, Moskowitz C, Comella CL, Goetz CC, Lang AE. A teaching videotape for the assessment of essential tremor. Mov Disord. 2001 Jan; 16(1):89-93. PMID: 11215599.
      View in: PubMed
    119. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5. PMID: 11094119.
      View in: PubMed
    120. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000; 55(12 Suppl 5):S15-21. PMID: 11188979.
      View in: PubMed
    121. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46. PMID: 10534248.
      View in: PubMed
    122. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8. PMID: 10534247.
      View in: PubMed
    123. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998 Aug; 51(2):526-9. PMID: 9710029.
      View in: PubMed
    124. Buchman AS, Comella CL, Leurgans S, Stebbins GT, Goetz CG. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6. PMID: 9613743.
      View in: PubMed
    125. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord. 1998 May; 13(3):552-5. PMID: 9613753.
      View in: PubMed
    126. Diederich NJ, Comella CL, Matge G, Becker G, Schiltz F, Metz H. Sustained effect of high-dose intrathecal baclofen in primary generalized dystonia: a 2-year follow-up study. Mov Disord. 1997 Nov; 12(6):1100-2. PMID: 9399251.
      View in: PubMed
    127. Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord. 1997 Jul; 12(4):570-5. PMID: 9251076.
      View in: PubMed
    128. Diederich NJ, Comella CL, Goetz CG. [Botulin toxin: principles of action and neurological indications]. Presse Med. 1997 Feb 01; 26(2):96-100. PMID: 9082423.
      View in: PubMed
    129. Comella CL, Goetz CG. Akathisia in Parkinson's disease. Mov Disord. 1994 Sep; 9(5):545-9. PMID: 7990849.
      View in: PubMed
    130. Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8. PMID: 8145901.
      View in: PubMed
    131. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 1993 Nov; 34(5):710-4. PMID: 8239565.
      View in: PubMed
    132. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10. PMID: 8504437.
      View in: PubMed
    133. Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology. 1992 Jul; 42(7):1307-10. PMID: 1620339.
      View in: PubMed
    134. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992 Apr; 42(4):878-82. PMID: 1565246.
      View in: PubMed
    135. Diederich N, Goetz CG, Comella CL. New approaches in the treatment of the dystonias. Klin Wochenschr. 1990 Oct 03; 68(19):935-41. PMID: 2232624.
      View in: PubMed
    136. Goetz CG, Tanner CM, Penn RD, Stebbins GT, Gilley DW, Shannon KM, Klawans HL, Comella CL, Wilson RS, Witt T. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 1990 Feb; 40(2):273-6. PMID: 2300248.
      View in: PubMed
    137. Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt TR. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004. PMID: 3419583.
      View in: PubMed
    138. Rogers WA, Valdez H, Anderson BC, Comella C. Partial deficiency of antidiuretic hormone in a cat. J Am Vet Med Assoc. 1977 Mar 01; 170(5):545-7. PMID: 557470.
      View in: PubMed
    Comella's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description